Safety of Anticoagulant Therapy After Endoscopic Treatment

Cirrhosis Clinical Trial

Official title: Initiation of NWS Anticoagulation Therapy After Oesophageal Variceal Band Ligation Was Safe in Portal Vein Thrombosis Patients With Cirrhosis and Acute Variceal Bleeding: A Multi-central Randomized Controlled Trial

Status Completed

Clinical Trial Summary

The investigators aimed to verify the efficacy and safety of nadroparin calcium warfarin sequential (NWS) anticoagulation therapy after endoscopic therapy in PVT patients with cirrhosis and AVB.

Clinical Trial Description

Acute variceal bleeding is one of the most serious complications of liver cirrhosis and is associated with significant morbidity and mortality. Portal vein thrombosis (PVT) aggravates portal hypertension and worsens hemorrhage, which Increases the risk of endoscopic therapy, and PVT has been shown to be associated with a longer time to variceal eradication, a higher risk of variceal relapse and rebleeding. So, PVT should be treated earlier. Data regarding the safety and initiation time of anticoagulant therapy in PVT patients with variceal bleeding after endoscopic therapy is lacking. Aim of this study is to verify the efficacy and safety of NWS anticoagulation therapy in PVT patients with cirrhosis and AVB after endoscopic therapy and further to explored the appropriate initiation time of NWS anticoagulation therapy after EVL in these patients. ;

Related Conditions & MeSH terms

• Anticoagulant-induced Bleeding
• Cirrhosis
• Esophageal and Gastric Varices
• Fibrosis
• Hemorrhage
• Liver Cirrhosis
• Portal Vein Thrombosis
• Thrombosis
• Venous Thrombosis

• NCT number: NCT04976543
• Study type: Interventional
• Source: Qilu Hospital of Shandong University
• Status: Completed
• Phase: Phase 4
• Start date: February 1, 2020
• Completion date: June 28, 2022